Pacira BioSciences (PCRX) Stock Price, News & Analysis

Company Overview

Pacira BioSciences, Inc. is a biopharmaceutical company specializing in non-opioid pain management and regenerative health solutions. Founded in 2006 and headquartered in Parsippany, New Jersey, the company is dedicated to developing innovative therapies that address acute and chronic pain while reducing reliance on opioid medications. Pacira’s research and development efforts focus on advanced drug delivery technologies designed to improve patient outcomes in surgical and postoperative settings.

The company’s flagship product, EXPAREL, is a liposomal bupivacaine injection that provides sustained postoperative analgesia for up to 72 hours, helping to reduce opioid consumption and enhance recovery protocols. Pacira also offers the iovera® cryoanalgesia system, which uses targeted cryotherapy to temporarily block nerve conduction and provide localized pain relief for orthopedic and surgical applications. In addition to commercial offerings, the company maintains a robust pipeline of investigational therapies aimed at expanding its portfolio of non-opioid analgesics and regenerative health products.

Pacira operates globally, with a commercial presence in North America, Europe, Latin America and the Asia Pacific region. The company works closely with hospitals, ambulatory surgery centers and specialty clinics to integrate its products into multimodal pain management pathways, offering training and education programs for anesthesiologists, surgeons and nursing professionals. Strategic partnerships and distribution agreements further support Pacira’s efforts to broaden access to its proprietary drug delivery platforms.

Under the leadership of President and Chief Executive Officer Jeremy A. Jacobs, Pacira has strengthened its operational capabilities and expanded its international reach. Supported by a seasoned executive team with expertise in pharmaceutical development, regulatory affairs and commercial strategy, the company continues to advance its mission of delivering safer, more effective pain management solutions and regenerative health innovations.

Key Stats

• Today's Range: $22.93 to $23.45
• 50-Day Range: $23.17 to $26.98
• 52-Week Range: $11.16 to $27.64
• Volume: 515,308 shs
• Average Volume: 906,442 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.44
• Consensus Rating: Hold

Pacira BioSciences Stock Analysis - MarketRank™

Pacira BioSciences scored higher than 71% of companies evaluated by MarketBeat, and ranked 296th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Pacira BioSciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Pacira BioSciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 6.64%

Earnings Growth

Earnings for Pacira BioSciences are expected to grow by 6.64% in the coming year, from $2.41 to $2.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pacira BioSciences is -10.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pacira BioSciences is -10.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pacira BioSciences has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.92% of the float of Pacira BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Pacira BioSciences has recently decreased by 3.95%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pacira BioSciences does not currently pay a dividend.

Dividend Growth

Pacira BioSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.89

Percentage of Shares Shorted

12.92% of the float of Pacira BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pacira BioSciences has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Pacira BioSciences has recently decreased by 3.95%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Pacira BioSciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pacira BioSciences this week, compared to 9 articles on an average week.

Search Interest

2 people have searched for PCRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pacira BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $146,199.00 in company stock.

Percentage Held by Insiders

Only 6.40% of the stock of Pacira BioSciences is held by insiders.

Percentage Held by Institutions

99.73% of the stock of Pacira BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PCRX Stock Analysis - Frequently Asked Questions

How have PCRX shares performed this year?

Pacira BioSciences' stock was trading at $18.84 on January 1st, 2025. Since then, PCRX stock has increased by 23.0% and is now trading at $23.17.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its earnings results on Tuesday, November, 2nd. The company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.07. The business's revenue was up 8.7% on a year-over-year basis.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pacira BioSciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 7/10/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PCRX
• CIK: 1396814
• Web: www.pacira.com
• Phone: (813) 553-6680
• Fax: 302-655-5049
• Employees: 720
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Pacira BioSciences: $26.44
• High Price Target: $65.00
• Low Price Target: $10.00
• Potential Upside/Downside: +14.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.28)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 9.61
• P/E Growth: N/A
• Net Income: -$99.56 million
• Net Margins: -14.78%
• Pretax Margin: -9.69%
• Return on Equity: 13.78%
• Return on Assets: 7.00%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 2.41
• Quick Ratio: 1.99

Sales & Book Value

• Annual Sales: $700.97 million
• Price / Sales: 1.53
• Cash Flow: $4.31 per share
• Price / Cash Flow: 5.37
• Book Value: $16.86 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 46,290,000
• Free Float: 43,328,000
• Market Cap: $1.07 billion
• Optionable: Optionable
• Beta: 0.48